1. Introduction to Digital Therapeutics for Pharmaceutical Companies2. Complex software algorithms are the real reason FDA is after LDTs3. Is PBM disruption on the horizon?4. FDA, AI, and ML in drug and device development: Opportunities and challenges5. Defining "vaccine": How immunization innovation is challenging our regulatory health care coverage agencies6. FDA is embracing AI - are you keeping pace